“On Wednesday, the Food and Drug Administration approved lenacapavir for the prevention of HIV. Clinical trial data from last year suggest just two injections a year provide near-complete protection against an HIV infection…The twice-yearly injection offers a more convenient alternative to the current standard of care for HIV prevention, a daily pill called Truvada. This pre-exposure prophylaxis (PrEP) is 99% effective at preventing HIV infection in clinical trials, but some people face significant barriers in taking a daily pill. One study found oral PrEP’s was only 26% effective in certain groups, in part because of skipped doses.”From NPR.